# CVS HEALTH Corp: Form 10-Q for the period ended Mar 31, 2011

- Company: [CVS HEALTH Corp](/companies/cvs.md) (CIK 64803)
- Form: 10-Q
- Filed: 2011-05-05
- Accepted by EDGAR: May 5, 2011, 16:17 ET
- Period: 2011-03-31
- Accession: 0001104659-11-026342
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/64803/000110465911026342/a11-8716_110q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/64803/000110465911026342/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2011-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2011-01-01 to 2011-03-31 | $25.88bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2011-01-01 to 2011-03-31 | $21.13bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2011-01-01 to 2011-03-31 | $4.75bn | us-gaap:GrossProfit |
| Operating income | 3 months, 2011-01-01 to 2011-03-31 | $1.31bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2011-01-01 to 2011-03-31 | $135.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2011-01-01 to 2011-03-31 | $464.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2011-01-01 to 2011-03-31 | $713.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2011-01-01 to 2011-03-31 | $0.52 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2011-01-01 to 2011-03-31 | $0.52 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2011-01-01 to 2011-03-31 | 1,371,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2011-01-01 to 2011-03-31 | $1.87bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2011-01-01 to 2011-03-31 | $309.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2011-01-01 to 2011-03-31 | $171.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 3 months, 2011-01-01 to 2011-03-31 | $467.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2011-03-31 | $2.16bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2011-03-31 | $18.38bn | us-gaap:AssetsCurrent |
| Total assets | at 2011-03-31 | $62.83bn | us-gaap:Assets |
| Current liabilities | at 2011-03-31 | $11.46bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2011-03-31 | $8.67bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2011-03-31 | $806.0m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2011-03-31 | $300.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2011-03-31 | $37.92bn | us-gaap:StockholdersEquity |

## Market risk

As filed, 679 characters.

As of March 31, 2011, the Company was party to interest rate swaps with notional amounts totaling $525 million. These interest rate swaps are intended to manage our exposure to interest rate risk associated with an anticipated long-term debt issuance. The fair value of these interest rate swaps as of March 31, 2011 was de minimis. A 10% change in market interest rates associated with these interest rate swaps would not result in a material change in the fair value of such financial instruments.

The Company believes that its exposure to market risk associated with other financial instruments, principally interest rate risk inherent in its debt portfolio, is not material.

## Controls and procedures

As filed, 5,576 characters.

**Evaluation of disclosure controls and procedures:** The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-15 (f) and 15d-15(f)) as of March 31, 2011, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.

**Changes in internal control over financial reporting:** There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the three months ended March 31, 2011 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Part II Item 1

### Legal Proceedings

Certain legal proceedings in which we are involved are discussed in Part I, Item 3 of our Annual Report on Form 10-K for the year ended December 31, 2010. The following discussion is limited to certain recent developments concerning our legal proceedings and should be read in conjunction with those earlier reports.

1\. In January 2010, the Company received a subpoena from the Inspector General, United States Department of Health and Human Services in connection with an investigation of possible false or otherwise improper claims for payment under the Medicare and Medicaid programs. The subpoena requested retail pharmacy claims data for “dual eligible” customers (i.e., customers with both Medicaid and other third party insurance coverage), information concerning the Company’s retail pharmacy claims processing systems, copies of pharmacy payor contracts and other documents and records. In April 2011, the Company announced that it had resolved this investigation by entering into a settlement with the Department of Justice, Department of Health and Human Services, and the Attorneys General of ten states (Alabama, California, Florida, Indiana, Massachusetts, Michigan, Minnesota, New Hampshire, Nevada, and Rhode Island). This settlement resolves a *qui tam* lawsuit that had been filed under seal pursuant to federal and state false claims act statutes. The settlement terms include payment by the Company of $17.5 million to the federal government and to the participating states and an amendment to the Company’s existing Corporate Integrity Agreement. The Company’s legal reserve related to this matter at March 31, 2011 was sufficient to cover the required settlement payments.

2\. In November 2009, a securities class action lawsuit was filed in the United States District Court for the District of Rhode Island purportedly on behalf of purchasers of CVS Caremark Corporation stock between May 5, 2009 and November 4, 2009. The lawsuit names the Company and certain officers as defendants and includes allegations of securities fraud relating to public disclosures made by the Company concerning the PBM business and allegations of insider trading. In addition, a shareholder derivative lawsuit was filed in December 2009, in the same court against the directors and certain officers of the Company. A derivative lawsuit is a lawsuit filed by a shareholder purporting to assert claims on behalf of a corporation against directors and officers of the corporation. This lawsuit includes allegations of, among other things, securities fraud, insider trading and breach of fiduciary duties and further alleges that the Company was damaged by the purchase of stock at allegedly inflated prices under its share repurchase program. In January 2011, both lawsuits were transferred to the United States District Court for the District of New Hampshire. The Company believes these lawsuits are without merit and the Company plans to defend them vigorously. The Company received a subpoena dated February 28, 2011 from the Securities and Exchange Commission (“SEC”) requesting, among other corporate records, information relating to public disclosures made by the Company in 2009 concerning its PBM and Medicare Part D businesses and information concerning ownership and transactions in the Company’s securities by certain officers of the Company. The Company is cooperating with these requests for information and has been providing documents and other information to the SEC as requested.

### Part II Item 2

### Unregistered Sales of Equity Securities and Use of Proceeds

(c) Stock Repurchases

The following table presents the total number of shares purchased in the three months ended March 31, 2011, the average price paid per share and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the 2010 Repurchase Program.

| Fiscal Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs |
| --- | ---: | ---: | ---: | ---: |
| January 1, 2011 through January 31, 2011 | — | $— | — | $2,000,000,000 |
| February 1, 2011 through February 28, 2011 | 7,806,313 | $32.84 | 7,806,313 | $1,743,635,778 |
| March 1, 2011 through March 31, 2011 | 6,371,553 | $33.05 | 6,371,553 | $1,533,060,654 |

28

### Part II Item 6

### Exhibits

Filed May 5, 2011.
Source: SEC EDGAR, the filing index for accession 0001104659-11-026342. Last ingested by Listed: Nov 6, 2026, 17:47 ET. No prices; not investment advice.
